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Theglycophorin A (GPA) assay isahuman mutationassaythatispotentiallyusefulforlargeepidemiological studies.
Theassay israpidandrequiresaminimalamountofblood, whichcanbestoredbeforeanalysis.Thedatapresentedhere
werecollected fromworkersexposedtostyreneinaboatmanufacturingplant.ThisstudywasthefirsttoapplytheGPA
assay toanoccupationallyexposed population. Subjectswithameanstyreneexposureof30ppmhadahigherfrequen-
cy ofGPA N4 variant cellsthansubjects with meanexposureof1 ppm, butthesubjectsdiffered in respect tosmoking
andagedistribution. Resultsindicatethattheoriginal l-W-1 versionoftheassaymay notbesuitableforstudiesofsmall
numbersofexposedsubjectsduetovariabilityandartifacts. ThenewerBR6version,however, hasmuchlowervariability
and shows promise for useintheoccupational setting.
Introduction
The glycophorin A (GPA) gene loss mutation assay estimates
genetic damage tohumansby measuring the frequency ofGPA-
variant red blood cells in peripheral blood samples (1,2). The
GPA assay hasadvantages fortheepidemiologist overtheother
mutation assayscurrentlyavailable,namely,thehprt,HLA-A,and
Hb-S assays(3). TheGPAassayisrapidandsimplecomparedto
thehprtandHLA-Aassays-theresults canbeobtained within48
hr, andthe assay requires aminimal (< 1 mL)bloodsamplethat
canbe storedfor upto2 weeks atrefrigeratortemperatures. The
GPA assay also presumably detects awider spectrum ofmuta-
tional mechanisms thanthe hprtandHb-S assays because GPA
variantcells may arisefrommutationsthatinvolvechromosome-
wide events orchromosomal interactions such asmitotic recom-
bination (2). The latter mechanisms have been found to be in-
volved in the loss of tumor-suppressor genes, as reviewed by
Grant et al. (4).
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There are also disadvantages to the GPA assay from the
epidemiologicalperspective; theGPAassay requires aspecific
bloodtype(MN)andsocanbeperformedononlyabout50% of
allsubjects, and, inaddition, itmeasuresmutationsinbonemar-
rowcellsonlybecausecirculatingredbloodcellslackanucleus.
Theeffectofexposuremustthereforepenetratetobonemarrow
toresultinaresponse. ElevatedfrequenciesofGPA-variantcells
havebeenfoundinsubjectsexposedtoionizingradiation(5,6),
inpatients receivinghighdosesofantineoplastic drugs (7), and
in persons with cancer-prone syndromes (8,9).
This study was undertaken to evaluate thepotential utility of
theGPA assay in alow-exposedpopulation moretypical ofen-
vironmentalepidemiology thanthehigh-dose/high-riskpopula-
tions, previously studied,usingtheoriginal l-W-I versionofthe
GPAassay (1) as well asa new and morepreciseversionofthe
assay (BR6)developed (2) during thetimeperiodofthe study.
ThedatapresentedhererepresentthefirstapplicationoftheGPA
assay to anoccupationally exposed population.
Materials and Methods
Determination ofGPAVariant Cell Frequency
TheGPAassay wasperformed essentially asdescribed(1,2).
Briefly, fixedredbloodcellsobtainedfromheterozygous(MN)
individualswerereactedwithfluorescentlylabeledmonoclonal
antibodiestoMandNformsofGPA. Aflowcytometerwasused
to measure fluorescence from each cell. Normal MN cellsCOMP7ON-QUINTANA ETAL.
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FIGURE 1. (A) Flow-cytometric measurements of-fluorescence from mixture
ofMM, MN, and NN cells stained with anti-M and anti-N antibodies. (B)
Results of BR6 assay using I million red blood cells from a low-exposed
styrene worker. Six N4 and nine NN GPA variant cells were found. The
average offive such assays was 5.5 N$ and7.5 NN variantcells per million
red cells.
fluoresce both red (anti-M antibody) and green (anti-N an-
tibody), and variant cells fluoresce green only; N4 variants
(missing theM form) showthe samelevelofgreenfluorescence
as normal cells, and NN variants showdouble thenormal green
fluorescence level. These two classes of variants presumably
arise throughdifferent mechanisms, gene inactivation and gene
duplication. Data outputs aretypically inthe formofhistograms
with green fluorescence on oneaxis and red ontheother, using
counts as athirddimension. Figure IA shows ahistogram from
theBR6 assayofamixtureofMM, MN, andNNbloodcellsthat
isused to setexpectationsforfluorescenceofvariantcells. Figure
[B is a histogram of 1 million cells from a workerexposed to a
low levelofstyrene. As canbe seen, variantcellscontributeonly
afew counts permillion MN redcellscounted. Thevariantcell
frequency, averaged over 5such runsof 1 millioncellseachfrom
this worker, was 5.5 N4 variants permillion and7.5NNvariants
per million.
Two versions ofthe GPA assay were used. Theoriginal (1),
known as l-W-1, used a dual-beam flow cytometer with sorter
(DBS). Thesorter was necessary becausetheantibody combina-
tionsusedfrequently generatedartifacts, especially NNartifacts,
in the fluorescence histograms, and visual confirmation of
separated variantcells was necessary. However, the sorter itself
introduced additional variability, andthe DBS isacomplex in-
strument requiring skilled maintenance. Obtaining a new an-
tibody combination allowed the development of a new assay
known as BR6 (2) based on a commercially available single-
beamflowcytometerwithoutasorter. TheBR6assay shows im-
provedprecision, especially forNNvariants, andmorecells can
be collected per subject, which reduces the variability due to
Poisson distribution ofrare events. The lower cost and ease of
operationofthecountertop, single-beamflowcytometer will aid
in export ofthis assay toother laboratories.
Study Population
The population studied was a group of workers in a boat-
manufacturing plantexposed to styreneduringhandlamination
ofthe boat hulls. Other plant employees with low styrene ex-
posures, such as maintenance workers, were used as controls.
Styreneoxideisacarcinogen inrodentsandstyreneand styrene
oxidearemutagenic inhumancellsin Witro. Cytogenetic studies
ofpeopleoccupationally exposedtostyrenevaporhavefound in-
creases inchromosomal aberrations, micronuclei, single-strand
DNA breaks, and unscheduled DNA synthesis in peripheral
lymphocytes [reviewed in Bond (10), Barale (11), and Maki-
Paakkanenetal. (12)].
This study was part ofa larger study at University of Cali-
forniaatBerkeley thatexamined multiple endpointsofstyrene
exposure: air levels, exhaled air levels, and blood levels of
styrene; adducts ofstyreneoxidetohemoglobin, albumin, and
DNA; glutathioneS-transferase enzymelevels inblood; micro-
nuclei frequencies and sisterchromatidexchange frequencies in
lymphocytes; and GPA variant frequencies in red blood cells
(13,14). Thiswasalongitudinal studydesigninwhichairandex-
haledairlevelsweredeterminedduringeightsurvey visitsover
thecourseof18 months, withblood samples beingobtained on
fiveofthesevisits. All workers were administered aconfiden-
tialquestionnaire todetermine pastexposures thatcould cause
genotoxic damage or could interfere with the assays used.
Results
Styrene Exposure ofSubjects
Overall, 61 workersparticipated inthestudy, with 37ofthem
having the MN blood type required for use ofthe GPA assay.
Workers were continuously recruited to the study between
surveys 1 and 5 to reach the maximum of37 MN subjects, and
enrollmentdeclinedinsurveys6,7, and8duetojobterminations,
absencesatthetimeofvisit, ortransfers toanothershift. Dueto
thedifficultyofobtainingsubjectsforthestudy, allworkerswill-
ing to participate were enrolled regardless of smoking status.
However, enrolled workers had to have worked inthe plant for
atleast 1 year. Blood samples were drawn on surveys 1, 3, 5, 7,
and8. Survey8wasmadespecifically toapply thethen-new BR6
assay to subjects inthe styrene study.
Job classification was found not tobe a reliable guide to ex-
posureclassification. Theworkerswhowereoriginallyenrolled
in the study as controls on the basis that they were employed
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FIGURE 2. Mean and SD ofstyrene concentration in breathing zone, meas-
ured foreachof30workers andaveraged overthestudy period. Workers were
assigned to exposure groups as shown. Inaddition tothe workers shown in
this figure, there were sixadditional workers inexposurecategory0andone
additional worker in category I for whom no airconcentrations ofstyrene
were measured. All additional workers wereassumed to have been exposed
to less than 10 mg/m3 ofstyrene because all worked in outbuildings.
intheplantbutdid notworkwith styreneallprovedtohavelow
butmeasurableexposuretostyrene, from0.25 to3.5 ppm (1-15
mg/m3). However, time-weighted average exposures to styrene
showed suprisingly little seasonal variation, so that workers
could begrouped intoexposurecategories based ontheiroverall
mean exposure. The workers were divided into exposure cate-
gories, as shown in Figure 2. Exposure category 4had average
exposures of 170 mg/m3 (40 ppm), and exposure category 3
averaged 55 mg/m3 (13 ppm), whereascategories 4and 3 com-
bined averaged 132 mg/m3 (32 ppm). Exposurecategory 0 was
made up of persons who had never worked with styrene and
category I ofthose notcurrently working with styrenebutwho
had previously worked with styrene. The distinction between
category 0 and category 1 was made because functionally im-
mortal stemcells in the bone marrowgive rise tothe red blood
cells measured, so that exposure to styrene in the past could
cause a current elevation in variant frequencies ifstyrene had
given rise to GPA-mutated stem cells. The mean exposure of
categories 1 and 0 combined was 1.2 ppm (5 mg/m3).
Styrene Exposure and GPA Variant Frequencies
TostudytheeffectofstyreneonGPAvariantfrequencies, com-
parisons were madeofvariantfrequency (permillion redcells)
ofworkers inexposure category 4(10workers) versuscategory
0(12 workers) andcategories4and 3combined (15 workers) ver-
suscategories I and0combined (15 workers). Whilecategories
4and0differmost in styreneexposure,differences invariantfre-
quency are hardertodetectwithsignificancebecausetheyhave
smallernumbers ofworkers thanthecombinedcategories. Inad-
dition, comparisons made using exposure category 4 are the
mostcompromisedfromtheepidemiologicalviewpoint, because
this category contains ahigherproportion ofolder women and
smokers thanany other category. TheGPA variant frequencies
measured in this study did not fit a normal or log-normal
distribution on statistical fit tests. Themedian values wereused
inall analyses soas to minimizetheeffectsofoutlier-measured
variant frequencies. Due to technical difficulties encountered
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FIGURE 3. Measurements using the BR6 assay on blood collected during final
survey. (A) N4' and (B) NNGPAvariantfrequency, comparedby workerex-
posuregroup. Thedataarepresented usingaboxplot format, anonparametric
presentation where the boxenclosesthe middle50% ofthedataand the me-
dian is shown as a line. The shaded areas representapproximately the95%
confidence interval ofthe median determined for that data set; (*) and (o)
represent outliers.
with using the original l-W-l assay forthe measurement ofNN
variants, specifically with the occurrence of artifacts that in-
crease measured frequencies ofNN variants, the decision was
madethatthemeasurementsofNNvariantfrequenciesusingthe
I-W-1 assay should notbeused. Thisconclusionwasalsoreached
by Kyoizumi et al. (15). The median values ofN4 variant fre-
quency (per million) measured using the 1-W-1 assay were:
categories4+3, median = 10.3comparedtocategories 1+0, me-
dian = 6.9 (p = 0.028) (all probabilities given are Mann-
Whitney). Category 4 had a median N4 of 10.8 per million, as
compared to 8.4 for category 0 (p = 0.088).
Two measurement runs were made on the blood from each
worker in each survey, and examination ofthe N4 variant fre-
quenciessuggested thattheresults fromthe second run showed
a higher variability than those from the first run. The NcI me-
diansofcategories4+3 comparedtocategories 1+0usingdata
fromthefirstrunonlyare9.64versus4.4, withp = 0.0164. Com-
paringcategory4withcategory0themedians are 8.5 versus4.9,
withp = 0.060.
Survey 8 was made to apply the new BR6 assay being de-
velopedatthattimetosubjects inthisstudy. Unfortunately, itwas
only possible to collect blood from 9 workers in categories
4+3 (down from 15 inearliersurveys). Figure 3 showsGPA me-
dian frequencies obtained usingtheBR6assay. For N4 variant
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frequencies, categories4+3 haveamedianof6.7 versus4.7 for
categories 1+0, withp = 0.087, whereascategory 4hasamedian
of 8.0 versus 3.5 for category 0, withp = 0.055. Again, these
results suggestan increase in N4 variantfrequency inthemore
highly exposed categories, but because the categories are not
directly comparable with respect to smoking andother factors
the effect could be due toexposures other than to styrene. The
results do not suggest any increase in the frequency of NN
variants with increasing styrene exposure.
Effect ofPossible Confounding Factors
Aclearseparationoftheeffectsofstyreneandsmokingisnot
possiblebecauseagreaterproportionofthesmokerswereexposed
to styrene: 50% ofthe smokers wereexposedcompared to25%
ofnonsmokers. Comparing factorby factor, thereis no indica-
tion ofaGPAvariantfrequency increasewith smoking, norwith
a history of X-ray exposure. An effect of age (< 40 or >40
years) is suggested intheNNvariantfrequency, both forallex-
posurecategories (p = 0.089) and forexposurecategories 1+0
(p = 0.036). For the NN variants, females appear to have a
greater variant frequency than males, both for all exposure
categoriescombined(p = 0.096)and inexposurecategories 1+0
(p = 0.0188). This effect is probably dueto the greaterpropor-
tion of subjects over 40 years old among females than among
males. Agetherefore seemstobethemajorconfounderforGPA
NN variant frequencies measured intheGPAassay (Compton-
Quintana etal., manuscript in preparation.)
Performance ofthe GPA Assay
Onegreatimprovementthathasresultedfromthedevelopment
of the BR6 version of the GPA assay is the reduction of the
variance in measurementsofGPA variant frequency. Thecoef-
ficientofvariation (CV) hasbeenreportedby Langlois etal.(2),
using fresh blood samples from 17 selected laboratory normal
donorsunderthemostfavorablelaboratoryconditions, tobe64%
forNcI and 132% for NNvariantfrequencies inthe I-W-l assay,
and30% and 19% forN4 andNN,respectively, intheBR6assay.
The results intheoccupational settingreportedhereshowacon-
siderably highervarianceusingthe 1-W-1 assay. Forsubjects in
exposurecategories 1 and0, theCVmeasuredusingthe 1-W-1 as-
say was 135% forN4 variantfrequenciesand 137% forNNvar-
iantfrequencies. Thesevalues fortheCV representwhatmight
beexpected fromthe I-W-1 GPAassay ifblood iscollected inthe
theoccupational settingandshipped foranalysisunderthecon-
ditions ofthis study. Using the BR6 assay, the CV was 27% for
N4 variant frequencies and24% for NN variantfrequencies.
Because inthis study multiplemeasurements weremadeper
workers, theeffectofthevarianceofthe 1-W-1 assay was mini-
mized andthe powerofthe l-W-I assay was increased toalevel
similar tothatofaone-time measurementusing theBR6assay.
This illustrates the importance oflongitudinal studies.
Discussion
One ofthe strengths ofthis study design is the longitudinal
characterization ofthe styrene exposureoftheworkers, reduc-
ing the possibility that workers are wrongly classified into
styreneexposure categories andalso increasing thepowerofthe
study through increasing the number of blood samples per
worker. However, the small numberofsubjects, thepresenceof
possibleconfounding factors suchas smoking, andthe low con-
centrationsofstyrenetowhichtheexposed workerswere infact
exposedalltendedtodecreasethecapabilityofthedetectanef-
fect, ifpresent, ofstyrene.
The frequency ofGPAN4I type variants but notNN variants
is increased inworkers morehighly exposed tostyrene, although
thelevelofstatistical significance isnotcompelling. Thefinding,
ifreal, thatthegenotoxiceffectofstyreneapparently increases
N4l-type GPA variants to a greater extent than than NN-type
variantsaccords withthefinding thatstyreneoxideand styrene
+S9areclassifiedasmutagensintheAmestestandotherassays.
Theseresults shouldbeconfirmedwith a larger numberofsub-
jects in exposure categories that are better matched for age,
gender, andsmoking, andsuch astudy is, infact, beingcarried
out (Bigbeeetal., manuscript inpreparation).
Theoriginal 1-W-1 versionoftheassayhasahighvariability,
which wouldmakedetectionofa small effectdifficult. Many of
the sources ofvariability in the GPA assay, however, have been
reduced or eliminated in the newer BR6 assay. The BR6 assay
therefore holds much morepromise forthe successful applica-
tionoftheGPAassay tooccupationally orenvironmentally ex-
posed populations. Data from this study suggest that age, and
possibly sex, are confounders in the GPA assay and should be
carefullycontrolledinfuturestudies. GPAvarantfrequency may
also be affected by individual susceptibility to mutation. Data
frompersonsgivenchemotherapy (7)demonstratedthatpatients
receiving a direct-acting chemotherapeutic agent had a more
uniformincreaseinGPAvariantfrequency thanthosereceiving
anagentrequiring metabolic activation, aprocessthatis known
to vary between individuals.
Insummary,theGPAassayhasbeenshowntohavebothunique
advantagesaswellasdisadvantages. Itisrapidandrequiresamin-
malamountofbloodforanalysis. However, itisclearthat more
characterization needs tobe made ofthe sources ofvariability,
including those present in the assay itself, those arising from
natural differences in MN variant frequency in the general
population, andthoseassociated withconfounders oftheassay,
before the GPA assay can be applied routinely for biological
monitoring studies. Untilsuchinformation isobtained, themost
productiveplanmaybetoobtainapre-andpost-exposure sam-
ple, to the extent feasible in theoccupational orenvironmental
setting, and use each subject as his orher own control.
This manuscript waspresented asaposterattheConferenceonBiomonitor-
ing and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona, Hawaii, 26
October-I November 1991.
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